Universität zu Köln

Kaehler, Katharina C., Eigentler, Thomas K., Gesierich, Anja, Heinzerling, Lucie, Loquai, Carmen, Meier, Friedegund, Meiss, Frank, Pfoehler, Claudia, Schlaak, Max, Terheyden, Patrick, Thoms, Kai M., Ziemer, Mirjana, Zimmer, Lisa and Gutzmer, Ralf (2018). Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol. Immunother., 67 (5). S. 825 - 835. NEW YORK: SPRINGER. ISSN 1432-0851

Full text not available from this repository.

Abstract

Background Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only been evaluated in a selected number of patients. Methods We performed a retrospective analysis in 14 German skin cancer centers for patients with metastatic melanoma and pre-existing AD treated with ipilimumab. Results 41 patients with 44 pre-existing AD were treated with ipilimumab (thyroiditis n = 15, rheumatoid n = 11, dermatologic n = 10, Crohn's disease/ulcerative colitis n = 3, neurological n = 2, sarcoidosis n = 2, pancreatitis n = 1). 3 out of 41 patients had two AD, 11 patients required immunosuppressants at the time of induction of ipilimumab. 12 patients (29.2%) experienced a flare of their pre-existing AD, mainly patients with rheumatoid or dermatologic diseases. Additional immune-related adverse events (irAEs) occurred in 12 patients (29.2%). In 23 patients (56%) neither a change of their AD nor additional irAEs were observed. Objective responses were seen in five patients (one complete remission, four partial remissions, 12.1%). Conclusion This is the largest series of patients with pre-existing AD and treatment with ipilimumab reported. Flares of pre-existing AD were observed but manageable. Response rates and occurrence of new irAEs were comparable to previous trials. Thus, in this patient subgroup, ipilimumab can be a treatment option after a thorough discussion of pros and cons and taking severity and activity of the preexisting AD into account.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kaehler, Katharina C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eigentler, Thomas K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gesierich, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Heinzerling, Lucie UNSPECIFIED UNSPECIFIED UNSPECIFIED Loquai, Carmen UNSPECIFIED UNSPECIFIED UNSPECIFIED Meier, Friedegund UNSPECIFIED UNSPECIFIED UNSPECIFIED Meiss, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfoehler, Claudia UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlaak, Max UNSPECIFIED UNSPECIFIED UNSPECIFIED Terheyden, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Thoms, Kai M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ziemer, Mirjana UNSPECIFIED UNSPECIFIED UNSPECIFIED Zimmer, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Gutzmer, Ralf UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-188405
DOI:	10.1007/s00262-018-2134-z
Journal or Publication Title:	Cancer Immunol. Immunother.
Volume:	67
Number:	5
Page Range:	S. 825 - 835
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0851
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTI-PD-1 THERAPY; ADVERSE EVENTS; PEMBROLIZUMAB; ASSOCIATION; ANTIGEN-4; DISEASE Multiple languages Oncology; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18840